Background
Tuberculosis (TB) is a deadly disease infecting 9.6 million people globally and accounts for 1.5 million deaths annually [
1]. Currently, BCG is the only available vaccine against TB, which is administered since 1974 under immunization program of World Health Organization (WHO) [
2,
3]. Unfortunately, continuous increase in the number of TB cases raises a question on the protective efficacy of BCG [
4‐
6]. Interestingly, BCG protects children from TB [
7], indicating that it has adequate antigenic repertoire to protect against
Mycobacterium tuberculosis (
Mtb). In contrast, it fails to safeguard adults from TB; which has been suggested to be due to its failure to generate long-lasting memory T cells [
8].
Many studies are in progress to bolster BCG efficiency to impart enduring immunity. Memory inducing cytokines like IL-7 and IL-15 have been shown to sufficiently augment the BCG induced memory T cells [
8]. Furthermore, booster dose of
Mtb antigen Acr1 entrapped in fusogenic-liposomes generated long-term memory T cells and improved BCG potency [
9]. Thus, it implies that the protective efficacy of BCG can be boosted through antigen-priming. Recently, we have synthesized a novel lipopeptide vaccine construct L91, which comprises of a promiscuous-peptide derived from Acr1 and the TLR2 agonist Pam2Cys [
5,
10]. L91 elicited both innate and adaptive immunity successfully through its Pam2Cys and peptide component, respectively [
5,
10]. TLR-2 promotes the generation of memory T cells, rescued Th1 cells from exhaustion and protected mice from chronic TB [
11]. Intriguingly, L91 elicited long-lasting memory T cells and protected mice and Guinea pigs from
Mtb infection [
10].
In the current study, we have demonstrated that the memory T cell generation and protection efficacy of BCG vaccine against Mtb could be significantly bolstered with L91 boosting of the BCG-vaccinated population. Specifically we observed improvement in the pool of enduring memory Th1 and Th17 responses, the cells that play crucial role in protection against Mtb. In future, this vaccination strategy may be implemented to protect people from TB.
Methods
Study design
Female BALB/c mice (6–8 week) were procured from the Experimental Animal Facility, CSIR-Institute of Microbial Technology, Chandigarh, India. Mice were immunized subcutaneously (sc) at the base of tail with the Danish strain of BCG (106 CFU/mouse). Twenty-one days later, BCG-primed mice were boosted twice with L91, at an interval of 14 days apart (BCG-L91). Control groups were immunized with BCG alone (BCG), placebo (PBS) or an antigenically irrelevant lipidated influenza virus hemagglutinin peptide (abbreviated as LH or Pam2Cys). Mice were aerosol challenged with Mtb (~100 CFU/mouse), 90 days after the last booster. Subsequently, animals were sacrificed after 90 days of Mtb challenge. Later, immunological (ex vivo), protection and histopathology studies were performed. To monitor the antigen specific T cell response, mice were sacrificed 30 days after Mtb infection, and cellular responses were examined following in vitro stimulation with L91, Pam2Cys and short term culture filtrate of H37Rv (ST-CF). In all the experiments, changes in the response on vaccination were compared among BCG-L91 and control BCG and placebo (PBS) groups or otherwise indicated.
Vaccine constructs used in study
Lipidated synthetic peptides used in the study were produced by solid phase synthesis method, as described elsewhere [
12]. The lipidated promiscuous peptide of sequence SEFAYGSFVRTVSLPVGADE was from the Acr1 antigen of
Mtb (L91). The control, non-mycobacterial, lipidated peptide (LH) sequence ALNNRFQIKGVELKS was from influenza virus hemagglutinin light chain and was shown to be active in BALB/c mice [
13].
Mycobacterial strains and BCG
Mtb H37Rv strain was cultured in 7H9 medium containing Tween-80 (0.05%), supplemented with albumin (10%), dextrose and catalase (ADC). Glycerol stocks of H37Rv were prepared and stored at −80 °C, and later used for infection studies. BCG vaccine (TUBERVAC) used for immunization was purchased from Serum Institute of India, Pune, India. TUBERVAC (Bacillus Calmette-Guerin Vaccine I.P.) is a live freeze-dried vaccine derived from an attenuated strain of Mycobacterium bovis and meets the requirements of WHO and I.P. when tested by the methods outlined in WHO, TRS. 745 (1987), 771 (1988) and I.P.
Reagents and antibodies
Chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO). Anti-mouse or anti-human fluorochrome labeled antibodies (Abs): CD4-PB, CD62L-APC, CD44-PerCP-Cy5.5, CD127-PE, FoxP3-FITC, Tim3-PE, PD1-PECy7, IFN-γ-PECy7, TNFα-PerCPCy5.5, IL-17-PerCPCy5.5, CD25APC-Cy7, CD45RA-PE, CD45RO-APC, and Abs for ELISA were procured from BD Pharmingen (San Diego, CA) or otherwise mentioned. RPMI-1640 and FBS were purchased from GIBCO (Grand Island, NY) for cell culture. For culturing of cells, tissue culture grade plastic-wares were purchased from BD Biosciences (Bedford, MA). Ab against iNOS used in Western blot was procured from (Abcam, Cambridge, United Kingdom).
Isolation of lymphocytes from lymph nodes, spleen and lungs
Spleens and LNs obtained from the immunized mice and exposed to Mtb, were pooled and single cell suspension was prepared by gently pressing through frosted slides. Lungs were perfused with chilled PBS and small pieces were prepared and digested with collagenase (2 mg/ml) for 30 min/37 °C. Later, cells were passed through a sieve (70 μM). Viability was checked by trypan blue dye-exclusion method and cells (2 × 105/well) were added to 96 well U-bottom culture plates and cultured with L91 (1 nmol), Pam2Cys (50 ng/ml), ST-CF (25 μg/ml) and medium for 72 h.
Proliferation assays
The cells (2 × 107 cells) were incubated with carboxyfluoresceinsuccinimidyl ester (CFSE) dye in PBS (1 μM, 4 ml) at 37 °C. Free CFSE was quenched with 2 ml of FCS and excess was removed by washing with RPMI-FCS-10%. CFSE-labeled cells were cultured with either L91 (1 nmol), Pam2Cys (50 ng/ml), ST-CF (25 μg/ml) or medium for 72 h. The proliferation of CFSE-labeled cells was analyzed by flow cytometry.
Intracellular cytokine and surface staining
The cells were stimulated as mentioned in the proliferation assay and then stimulated with PMA (50 ng/ml) and ionomycin (10 μM) for 4 h followed by incubation with brefeldin A (5 mg/ml) for an additional 2 h. The cells were then harvested, washed twice with buffer (PBS-FCS-2%) and fixed with paraformaldehyde (1X) at 4 °C for 30 min. Fixed cells were perforated with saponin (0.2%) and incubated with fluorochrome tagged anti-IFN-γ, IL-17A and TNF-α Abs at 4 °C for 90 min. The cells were washed with saponin (0.2%), followed by wash buffer. For surface staining, the cells were incubated with either fluorochrome labeled Abs or biotinylated Abs/streptavidin-fluorochrome conjugates. Standard protocols of washing/incubation were followed at each stage.
Flow cytometry
Flow cytometry was carried out using a FACS-Aria III and data was analyzed using the BD FACS DIVA software package (BD Biosciences, San Jose, CA). The gating strategies for FoxP3, PD-1, Tim-3, IFN-γ/TNF-α, IFN-γ/IL-17, CD62L/CD44, CD127 (Additional file
1: Figure S1) and CCR6/CXCR3 expression on IL-17/IFN-γ double positive cells (Additional file
2: Figure S2) have been shown in their respective figures.
Cytokine estimation
The cultures were set as mentioned in T cell proliferation assay. Later, culture supernatants (SNs) were collected and cytokine concentrations were determined using a standard sandwich ELISA [
14].
Culture of dendritic cells
Monocytes were isolated from the femurs and tibia of the mice. The cells (2 × 106/well) were cultured in the presence of granulocyte macrophage colony-stimulating factor (GM-CSF; 2 ng/ml) and interleukin-4 (IL-4; 4 ng/ml) for the generation of DCs. On day 3, the cultures were replenished with fresh medium and supplemented with GM-CSF and IL-4. On day 6, the cells were harvested, washed and added to 24 well plates (2 × 105 cells/well). Bone marrow derived dendritic cells (BMDCs) were stimulated with either L91 (3 nmol), F91 (3 nmol), Pam2Cys (50 ng/ml) or LPS (4 μg/ml) for 16 h. SNs were collected for cytokines estimation by ELISA and the expression of surface markers was assessed by flow cytometry.
Western blotting for iNOS
As mentioned above for the cultures of DCs and macrophages, BMDCs were stimulated with L91, F91, Pam2Cys and LPS for 16 h in 12 well plate (106 cells/well). The cells were harvested and lysed in radioimmunoprecipitation assay buffer (RIPA) containing a protease inhibitor cocktail. Protein was estimated and equal amounts (30 μg) were subjected to SDS-PAGE (10%) followed by transfer to PVDF membrane. The non-specific sites were blocked with BSA (5%) and the blot was probed with anti-iNOS Abs (1:200) (Ab3523) or actin as a control. Later, the blot was probed with anti-rabbit-HRP Ab and finally developed using an enhanced chemiluminescence method (Lumigen, Inc. Southfield, MI). The blot was finally scanned using Image Quant LAS 4000 (GE Healthcare, Pittsburgh, PA).
Demonstration of NF-κB by EMSA
BMDCs were stimulated with L91 (9 nmol), F91 (9 nmol), Pam2Cys (150 ng/ml) or LPS (4 μg/ml) for 30 min in 12 well plates (106 cells/well). The cells were harvested and nuclear extract was prepared. Nuclear extracts of each sample were incubated with [P32] labeled oligonucleotides containing the binding site for NF-κB at 37 °C for 20 min to allow the formation of DNA–protein complexes, which was then resolved by native gel electrophoresis using a 6% gel. Later, the gel was dried and exposed to a blank screen at room temperature for 6–10 h and scanned by a phosphorimager (Fujifilm, Tokyo, Japan).
Isolation and culture of human PBMCs
Blood was obtained from BCG vaccinated healthy volunteers in sterile vacutainers. Blood was diluted with PBS in 1:1 ratio and overlaid on histopaque. Peripheral blood mononuclear cells (PBMCs) were separated by centrifugation at 400 g for 30 min at 25 °C. PBMCs were washed 3 times with PBS + 2% FCS and in vitro cultured with L91 (1 nmol), F91 (1 nmol) or Pam2Cys (50 ng/ml) for 96 h. During culture, IL-2 (100U) was added after 24 h.
Statistical analysis
The data are presented as mean ± standard error. Statistical analysis was performed using Graph Pad Prism employing an unpaired Student’s ‘t’test.
Discussion
The slow progress of the ‘Stop TB Program’ and the emergence of drug resistant strains of
Mtb poses an urgent challenge for the scientific community to develop an effective vaccine against
Mtb. BCG is the only currently available vaccine, which is widely administered worldwide [
10]. Nevertheless, TB accounts for 9.6 million new cases and 1.5 million mortality annually [
1]. In many ways BCG is a controversial vaccine, since it protects 80% of individuals in non-TB endemic regions and 0% in TB-endemic zones [
7,
29]. BCG protects children but not adults living in TB-endemic regions, further demonstrating its variable efficacy [
5,
10,
30]. Many approaches to improve BCG vaccine have been tried, which includes recombinant BCG with different antigenic formulations [
29‐
31]. However, the introduction of a globally effective vaccine candidate, at least in TB-endemic zones, is yet to be achieved. The high protective efficacy of BCG in the developed world and children of TB-endemic sectors suggest that BCG has the adequate antigenic repertoire to protect against
Mtb [
23]. Nevertheless, BCG efficacy wanes with age, which indicates its failure to elicit life-long immunity [
32]. In this context, several approaches are being tried to boost BCG ability to generate enduring memory T cells and protection against TB [
8,
9].
L91 is a chimeric peptide comprising of MHC-II binding peptide and Pam2Cys and promotes the generation of long-term memory CD4 T cells [
10]. Therefore, we were encouraged to test the potential of L91 to bolster BCG efficacy by promoting the persistence of memory CD4 T cells and consequently long lasting protection against
Mtb.
We carried out a study in which L91 was used to boost the immune response primed by BCG vaccination. As compared to BCG group, the following major findings have been obtained: (i) significant reduction in the number of CFU in the lungs and diminished pathological changes in the Mtb infected mice; (ii) higher proliferation of the CD4 T cells and upregulated expression of IFN-γ and IL-17A; (iii) robust increase in the pool of multifunctional Th1 cells (IFN-γ+/TNF-α+) and Th17 cells (IL-17+/IFN-γ+/CXCR3+/CCR6+); (iv) expansion in the percentage of central and effector memory CD4 T cells; (v) the mechanism involved in the reduction of bacterial burden was through iNOS and TNF-α; (vi) the PBMCs obtained from the BCG vaccinated volunteers showed increase in the frequency of polyfunctional Th1 cells, Th17 cells and memory CD4 T cells on in vitro exposure to L91.
One of the main reasons associated with the weak efficacy of BCG vaccine to protect against
Mtb is attributed to the generation of Tregs following immunization, which dampens Th1 immunity through release of IL-10 [
33‐
35]. The decrease in the frequency of Tregs in the BCG-L91 group compared to BCG group clearly indicates the importance of L91 boosting in reducing the number of Tregs. The inhibition in the development of Tregs by BCG-L91 may be due to the augmented secretion of IFN-γ by Th1 cells [
36,
37]. Furthermore, the signaling events stimulated by TGF-β are negatively regulated by IFN-γ [
38]. TGF-β is responsible for the differentiation of naïve CD4 T cells to Tregs. IFN-γ-mediated phosphorylation of STAT1 leads to the expression of T-bet and Smad7 [
38,
39], which is known to suppress the regulatory function of Tregs [
40].
It has also been well documented that
Mtb drives Th1 cells to exhaustion [
11]. Th1 cells play a crucial role in protecting against
Mtb [
10,
11]. Recently, we have demonstrated that triggering of TLR-2 with Pam2Cys can enhance the generation of memory Th1 cells and rescues them from exhaustion by downregulating PD-1 and Tim-3 and amplifying co-stimulatory signals and the secretion of pro-inflammatory cytokines [
10,
11]. TLR-2 agonist Pam2Cys is a major component of L91. TLR-2 signaling not only rescues T cells from exhaustion but also stimulates both innate and adaptive immunity. Further, the higher susceptibility of TLR-2
−/− animals to
Mtb indicates an important role of TLR-2 in protection [
41,
42].
The induction of Th1 immunity plays a fundamental role in protecting against intracellular pathogens such as
Mtb [
7,
8,
10]. Further, MyD88
−/− animals with partially compromised Th1 immunity are more susceptible to TB [
15]. We demonstrated that the L91 booster substantially augmented Th1 immunity, as evidenced by improvement in IFN-γ secretion. Pam2Cys is known to stimulate DCs to release IL-12 through TLR-2 signaling [
10]. IL-12 is a differentiating factor for Th1 cells. Thus, L91 preferentially expands Th1 cells. Furthermore, we noted the generation of Th17 cells in the animals vaccinated with BCG-L91. Recently, it was demonstrated that Th17 cells confer protection against
Mtb by recruiting Th1 cells to the site of infection. Th17 cells show a robust effect on chemokine-mediated infiltration of macrophages and neutrophils at the site of infection [
17,
18].
It has been shown that the protective role of polyfunctional Th1 cells (IFN-γ
+/TNF-α
+) and Th17 cells (IFN-γ
+/IL-17A
+) is qualitatively superior to their single cytokine secreting counterparts, since they can effectively restrict the survival of
Mtb [
10,
17]. Interestingly, we found that BCG-L91 immunization expanded IFN-γ and TNF-α secreting polyfunctional Th1 cells. IFN-γ is known to activate macrophages and increase their bactericidal effect and TNF-α restricts the growth of
Mtb [
43,
44]. Such Th17 cells are reported to have a better protective capacity than single cytokine secreting cells [
17,
18,
45]. Further, Th17 cells expressing CXCR3
+CCR6
+ are associated with protection against
Mtb, while those displaying CCR6
+ CCR4
+ are involved in autoimmunity [
17,
45]. We found in this study that L91 preferentially expanded polyfunctional Th17 cells displaying CXCR3 and CCR6. Consequently, suggesting non-pathogenic nature of Th17 cells.
The importance of NO has been well documented in the killing of
Mtb by inducing apoptosis of infected cells [
27]. L91 activates DCs and augments the expression of iNOS and TNF-α. Both NO and TNF-α cumulatively protect the host from
Mtb and the mechanism deciphered is by inducing apoptosis of
Mtb-infected cells. Apoptosis releases intracellular bacteria, which provides an opportunity for the activated macrophages to engulf and eliminate them [
27]. We have shown that a booster dose of L91 efficiently bolsters the protective efficacy of BCG and significantly constrains bacterial burden in the lungs and spleen even after a lengthy period of 229 days of vaccination. The results of protection study suggest that L91 has a unique capability of generation and maintenance of long-lasting memory CD4 T cells and protection against
Mtb [
10].
Finally, we validated the efficacy of L91 employing PBMCs of BCG vaccinated healthy adult volunteers from TB-endemic and non-endemic zones. Importantly, CD4 T cells exhibited an enhacement in the expression of IFN-γ and IL-17A on in vitro stimulation with L91. Furthermore, an increase in the frequency of polyfunctional Th1 cells and Th17 cells was detected. Finally, it is worth to mention here that a remarkable expansion in the pool of memory CD4 T cells was found in our study, which illustrates the role of L91 in reinvigorating BCG efficacy to evoke long-lasting immunity responsible for protection against Mtb.
Authors’ contributions
Conceived and designed the experiments: PKR, JNA, DCJ. Performed the experiments: PKR, SBC, SN, WZ, SKM and SP. Analyzed the data: PKR, JNA. Contributed reagents/materials/analysis tools: WZ, AKJ and DCJ. Wrote the paper: PKR and JNA. All authors read and approved the final manuscript
.